PXL/HO/Cir-049/2023-24 Date: 08.09.2023
Subject: Market Research Report on the Pharmaceutical Sector in Oman
In continuation to our circular PXL/HQ/Cir-015/2022-23, Dt:17.05.2022 sharing the Market Research Report on the Pharmaceutical Sector in Oman, we are pleased to inform that Pharmexcil has received a communication from the Department of Pharmaceuticals and our Embassy of India in Oman regarding International cooperation efforts being taken in the area of Pharmaceutical sector with the Sultanate of Oman.
It is learnt that during the 10th India-Oman Joint Commission Meeting held on May 11, 2022, Indian side requested Omani side to consider/accept Indian pharmaceutical products which have been registered with USFDA, UKMHRA and EMA without need to go through the lengthy registration process in Oman for each product. Further, the Indian side requested the Omani side for fast tracking of applications of registration/approval of drugs/companies that are already approved by USFDA. The Omani side welcomed the proposals and agreed to expedite the review of registration of applications of products that are approved by USFDA, UKMHFA or EMA.
Towards this end, the Department of Pharmaceuticals has requested the Council to provide the list of interested companies who want to register their products, which are already approved by USFDA or UKMHFA or EMA, in Oman.
In view of the above, we kindly request our member exporters who have USFDA, UKMHRA or EMA and are interested in registering their products in Oman, to express their interest by filling up the below form latest by 15th Sep 23.
Google form link: